Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nguyen H Tran

Showing results (31-40 of 56) with videos related to

Pageof 6
Sort By:
Human Pathology|September 30, 2021
Morphological heterogeneity in beta-catenin-mutated hepatocellular carcinomas: implications for tumor molecular classificationMichael Torbenson, Chantal E McCabe, Daniel R O'Brien, et al.
JCO Precision Oncology|June 30, 2022
Tumor Mutational Burden Is a Potential Predictive Biomarker for Response to Immune Checkpoint Inhibitors in Patients With Advanced Biliary Tract CancerSavannah S Liddell, Sakti Chakrabarti, Grant A Wintheiser, et al.
International Journal of Radiation Oncology, Biology, Physics|September 9, 2019
Phase 2 Trial of Neoadjuvant FOLFIRINOX and Intensity Modulated Radiation Therapy Concurrent With Fixed-Dose Rate-Gemcitabine in Patients With Borderline Resectable Pancreatic CancerNguyen H Tran, Vaibhav Sahai, Kent A Griffith, et al.
Annals of Surgical Oncology|August 14, 2025
Real-World Single-Center Experience with Neoadjuvant Gemcitabine, Cisplatin, and Durvalumab in Borderline Resectable CholangiocarcinomaYawen Dong, Vanja Podrascanin, Zhihao Li, et al.
Annals of Surgical Oncology|August 5, 2025
Conversion to Resection After Neoadjuvant Gemcitabine, Cisplatin, and Nab-Paclitaxel for Borderline Resectable CCA: A Real-World Exploratory AnalysisYawen Dong, Jonas Santol, Vanja Podrascanin, et al.
Targeted Oncology|September 2, 2022
Outcomes following FGFR Inhibitor Therapy in Patients with CholangiocarcinomaJennifer J Gile, Vanessa Wookey, Tyler J Zemla, et al.
Cancers|June 13, 2025
Real-World Experiences Using Atezolizumab + Bevacizumab for the Treatment of Unresectable Hepatocellular Carcinoma: A Multicenter StudyMaen Abdelrahim, Abdullah Esmail, Richard D Kim, et al.
Annals of Surgical Oncology|June 26, 2026
The Effect of Neoadjuvant Therapy on Post-Recurrence Overall Survival After Curative Resection for Intrahepatic CholangiocarcinomaYawen Dong, David Pereyra, Vanja Podrascanin, et al.
In Vivo (Athens, Greece)|August 31, 2023
Therapeutic Efficacy of Temsirolimus in a Patient-derived Model of Metastatic Fibrolamellar Hepatocellular CarcinomaJennifer L Leiting, Matthew C Hernandez, John R Bergquist, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|May 17, 2026
Perioperative and oncologic outcomes of vascular resection after neoadjuvant therapy in intrahepatic cholangiocarcinomaYawen Dong, David Pereyra, Zhihao Li, et al.
Pageof 6

Showing results (31-40 of 56) with videos related to

Sort By:
Pageof 6
Human Pathology|September 30, 2021
Morphological heterogeneity in beta-catenin-mutated hepatocellular carcinomas: implications for tumor molecular classificationMichael Torbenson, Chantal E McCabe, Daniel R O'Brien, et al.
JCO Precision Oncology|June 30, 2022
Tumor Mutational Burden Is a Potential Predictive Biomarker for Response to Immune Checkpoint Inhibitors in Patients With Advanced Biliary Tract CancerSavannah S Liddell, Sakti Chakrabarti, Grant A Wintheiser, et al.
International Journal of Radiation Oncology, Biology, Physics|September 9, 2019
Phase 2 Trial of Neoadjuvant FOLFIRINOX and Intensity Modulated Radiation Therapy Concurrent With Fixed-Dose Rate-Gemcitabine in Patients With Borderline Resectable Pancreatic CancerNguyen H Tran, Vaibhav Sahai, Kent A Griffith, et al.
Annals of Surgical Oncology|August 14, 2025
Real-World Single-Center Experience with Neoadjuvant Gemcitabine, Cisplatin, and Durvalumab in Borderline Resectable CholangiocarcinomaYawen Dong, Vanja Podrascanin, Zhihao Li, et al.
Annals of Surgical Oncology|August 5, 2025
Conversion to Resection After Neoadjuvant Gemcitabine, Cisplatin, and Nab-Paclitaxel for Borderline Resectable CCA: A Real-World Exploratory AnalysisYawen Dong, Jonas Santol, Vanja Podrascanin, et al.
Targeted Oncology|September 2, 2022
Outcomes following FGFR Inhibitor Therapy in Patients with CholangiocarcinomaJennifer J Gile, Vanessa Wookey, Tyler J Zemla, et al.
Cancers|June 13, 2025
Real-World Experiences Using Atezolizumab + Bevacizumab for the Treatment of Unresectable Hepatocellular Carcinoma: A Multicenter StudyMaen Abdelrahim, Abdullah Esmail, Richard D Kim, et al.
Annals of Surgical Oncology|June 26, 2026
The Effect of Neoadjuvant Therapy on Post-Recurrence Overall Survival After Curative Resection for Intrahepatic CholangiocarcinomaYawen Dong, David Pereyra, Vanja Podrascanin, et al.
In Vivo (Athens, Greece)|August 31, 2023
Therapeutic Efficacy of Temsirolimus in a Patient-derived Model of Metastatic Fibrolamellar Hepatocellular CarcinomaJennifer L Leiting, Matthew C Hernandez, John R Bergquist, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|May 17, 2026
Perioperative and oncologic outcomes of vascular resection after neoadjuvant therapy in intrahepatic cholangiocarcinomaYawen Dong, David Pereyra, Zhihao Li, et al.
Pageof 6